The decision to use newer agents in relapsed/refractory follicular lymphoma is heavily influenced by the disease’s inherent ...

FDA approved triplet therapy for relapsed/refractory LBCL, including specific subtypes, for patients ineligible for auto-HSCT or CAR T-cell therapy. The therapy includes brentuximab vedotin, ...

Rituximab is a chimeric mouse–human monoclonal antibody (mAb) that targets the B-cell surface marker CD20 with high affinity. CD20 expression spans the developmental stages from the pre-B cell until ...

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases. However, the ...

Please provide your email address to receive an email when new articles are posted on . Learning from 2 decades of off-label rituximab use in systemic lupus erythematosus may point the way toward ...